arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

BIOMERICA INC

BMRA
$2.63 ▼ -0.10 (-3.66%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
64 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOMERICA INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 16.8%
Op. Margin -175.2%
ROIC -58.6%
FCF / Share None
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$875.00K
↑ +16.8%
Net Income Profit after all expenses
$-1.15M
↑ +25.8%
Operating Margin Operating profit as % of sales
-175.2%
↓ -33.2% 0th
FCF / Share Free cash flow per share
$-0.42
↓ -21.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 64 quarters